Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis

Rheumatology International

Volumn 23, Issue 3, 2003, Pages 134-137

  Aggarwal, Amita ^a   Misra, Ramnath ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cytokine; Disease modifying antirheumatoid drugs; Immunomodulation

Indexed keywords

ANTIRHEUMATIC AGENT; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG INHIBITION; DRUG MECHANISM; HUMAN; IMMUNOMODULATION; JUVENILE RHEUMATOID ARTHRITIS; PRIORITY JOURNAL;

EID: 0037836114     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-002-0267-y     Document Type: Article

References (15)

1. Ginnani EH, Brewer EJ, Kuzima N, Shakiov A, Maximov A, Vorontsov I, Fink CW, Newman AJ, Cassidy JT, Zemel LS (1992) Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double blind placebo controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Study Group. N Engl J Med 326:1043-1049
2. Seitz M (1999) Molecular and cellular effects of methotrexate. Curr Opin Rheumatol 11:226-232
3. Cornstein BN (1997) The mechanism of action of methotrexate. Rheum Dis Clin North Am 23:739-755
4. Chang DM, Weinblatt ME, Schur PH (1992) The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis. J Rheumatol 19:1678-1682
5. Seitz M, Zwicker M, Loetscher P (1998) Effect of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes. Arthritis Rheum 41:2032-2038
6. Wascher TC, Hermann J, Brezineschek R et al (1994) Serum levels of interleukin-6 and tumor necrosis factor alpha are not correlated to disease activity in patients with rheumatoid arthritis after treatment with low dose methotrexate. Eur J Clin Invest 24:73-75
7. Barrera P, Boerbooms AMT, Janssen EM et al (1993) Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha and interleukin-6 levels in rheumatoid arthritis: longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 36:1070-1079
8. Cassidy JT, Levinson JE, Bass JC, Baum J, Brewer EJ Jr, Fink CW, Hanson V, Jacobs JC, Masi AT, Schaller JG, Fries JF, McShane D, Young D (1986) A study of classification criteria for the diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum 29:274-281
9. Crilly A, McIness JB, McDonald AG et al (1995) Interleukin-6 (IL-6) and IL-2 receptor levels in patients with rheumatoid arthritis patients treated with low dose oral methotrexate. J Rheumatol 22:224-226
10. Seitz M, Dayer JM (1998) Stimulation of TIMP-1 production in rheumatoid arthritis upon MTX treatment. Z Rheumatol 57 [Suppl 1]:122
11. Seitz M, Loetscher P, Dewald B et al (1996) Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta and IL-8 - markers of remission in rheumatoid arthritis during treatment with methotrexate. J Rheumatol 23:1512-1516
12. Barrera P, Haagsma CJ, Boerbooms AMT, Van Riel PLCM, Borm GF, Van De Putte LBA, Van Der Meet JWM (1995) Effect of methotrexate alone or in combination with sulphasalazine, on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Br J Rheumatol 34:747-755
13. Willam AS, Punn YL, Amos N et al (1995) The effect of liposomally conjugated methotrexate upon mediator release from human peripheral blood monocytes. Br J Rheumatol 34:241-245
14. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS (1996) Inhibition of TNF-alpha expression by adenosine: role of A3 receptors. J Immunol 56:3435-342
15. Hildner K, Finotto S, Becket C, Schlaak J, Schirmacher P, Galle PR, Marker-Hermann E, Neurath MF (1999) Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis. Clin Exp Immunol 118:137-146